Biotech / Clinical Trials
Atrium doses first patient in first PRKAG2 trial, with proof-of-concept data guided to 2027
The Phase 1/2 Corventis study will enroll approximately 37 participants and test ATR 1072, an antibody oligonucleotide conjugate designed to silence mutant PRKAG2 messenger RNA. The 8-K carries no quarterly financial results.